Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy.
Lu J, Zhong H, Chu T, Zhang X, Li R, Sun J, Zhong R, Yang Y, Alam MS, Lou Y, Xu J, Zhang Y, Wu J, Li X, Zhao X, Li K, Lu L, Han B.
Lu J, et al. Among authors: zhong r, zhong h.
Eur Respir J. 2019 Mar 7;53(3):1801562. doi: 10.1183/13993003.01562-2018. Print 2019 Mar.
Eur Respir J. 2019.
PMID: 30578392
Free article.
Clinical Trial.